Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms

Inclusion Criteria: * 1\. A diagnosis of a ruptured brain aneurysm deemed suitable for repair by neuroendovascular techniques involving intraluminal occlusion by detachable platinum coils, or any neuroendovascular technique such as balloon-assisted coiling, stenting, or flowed diversion. * 2\. Patient should be Grade II-IV on the WFNS grading scale for SAH. * 3\. Male or female with a minimum age of 18 years on the day of enrolment. * 4\. Female subjects of childbearing potential: Negative pregnancy test. * 5\. Non-surgically sterile males or males with partners of childbearing potential must be willing to use condoms with spermicide for 3 months after completion of dosing. * 6\. Body weight less than or equal to 180 kg. * 7\. Vital signs on admission: * Blood pressure between 80-180 mm Hg systolic/50-100 mm Hg diastolic; * Body temperature ≤ 38.5C. * 8\. Informed consent and availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements. Exclusion Criteria: * 1\. Prior SAH within 6 months of presentation. * 2\. Dissecting or mycotic brain aneurysm. * 3\. Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment. * 4\. Known history of life-threatening allergic reaction to any medication. * 5\. Chronic renal disease defined as a baseline serum creatinine \> 150 µmol/L. * 6\. Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test. * 7\. Women who are breastfeeding. * 8\. Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol. * 9\. Pre-morbid (estimated) modified Rankin scale score of \>1. * 10\. Previous major stroke. * 11\. Patients with known HIV infection. * 12\. Participation in a clinical trial with an investigational drug within 30 days preceding this study. * 13\. Previous participation in the ENACT trial (e.g, to treat a prior aneurysm), participation in another trial involving NA-1 or prior receipt of NA-1. * 14\. Any other medical condition that the site investigator deems would put the patient at excessive risk of participation in the study or an expected life expectancy less than 1 year or that would result in inability to collect clinical outcomes at 90 days.